

Article

Prognostic Role of CSF β -amyloid 1–42/1–40 Ratio in Patients Affected by Amyotrophic Lateral Sclerosis

Tiziana Colletti ¹, Luisa Agnello ², Rossella Spataro ³, Lavinia Guccione ¹, Antonietta Notaro ¹, Bruna Lo Sasso ², Valeria Blandino ⁴, Fabiola Graziano ⁴, Caterina Maria Gambino ², Rosaria Vincenza Giglio ², Giulia Bivona ², Vincenzo La Bella ¹, Marcello Ciaccio ^{2,†} and Tommaso Piccoli ^{4,†,*}

Supplementary Table 1. Neuropsychologic assessment of ALS patients by FrSBe, MMSE and ECAS at time of diagnosis (baseline).

Neuropsychologic Tests	Median	IQR
FrSBe	53	45.5–57.5
MMSE	27.7	24.3–29.5
ECAS	101	85–115

Supplementary Table 2. Multivariate Cox regression analysis for overall survival for ALS patients considering their comorbidities.

Parameters	b	± SE	p	HR	95% C.I.
Smoke (yes <i>vs</i> no)	−0.090	0.410	0.826	0.914	0.409–2.041
Dermatological disorders (yes <i>vs</i> no)	−0.424	0.671	0.528	0.655	0.176–2.438
Respiratory disorders (yes <i>vs</i> no)	0.207	0.469	0.659	1.230	0.491–3.084
Otorhinolaryngological disorders (yes <i>vs</i> no)	0.260	0.576	0.652	1.297	0.419–4.015
Eye disorders (yes <i>vs</i> no)	0.610	0.595	0.306	1.840	0.573–5.904
Cardiovascular disorders (yes <i>vs</i> no)	0.623	0.319	0.05	1.865	0.999–3.483
Muscle-Skeletal disorders (yes <i>vs</i> no)	0.129	0.337	0.702	1.137	0.588–2.201
Gastroenteric disorders (yes <i>vs</i> no)	−0.220	0.313	0.492	0.803	0.434–1.484
Genitourinary disorders (yes <i>vs</i> no)	0.018	0.436	0.917	0.815	0.363–1.827
Dysmetabolic disorders (yes <i>vs</i> no)	−0.205	0.412	0.619	0.815	0.363–1.827
Psychic disorders (yes <i>vs</i> no)	−0.012	0.456	0.979	0.988	0.404–2.416
Hematologic disorders (yes <i>vs</i> no)	−0.22	0.524	0.675	0.803	0.288–2.240
A β 42/40 ratio	−22.0018.889	0.013	*2.79E-100	0.000	0.010